Researchers from Sichuan Baili Pharmaceutical Co. Ltd. and Systimmune Inc. presented preclinical data for the novel CD33-targeting antibody-drug conjugate (ADC) being evaluated for the treatment of hematologic malignancies.

α-Fetoprotein (AFP) is a tumor-associated antigen and an ideal target for T-cell receptor T-cell (TCR-T) therapy. While the safety of AFP-targeting TCR-T products has been previously demonstrated in early clinical trials, the efficacy of these cell therapies is still modest, warranting further research.

Researchers from Gempharmatech Co. Ltd. presented a new humanized mouse model for preclinical research into the functionality and therapeutic potential of IL-12.

Researchers from ADC Therapeutics SA presented the discovery and preclinical evaluation of a novel camptothecin-based Claudin-6-specific antibody-drug conjugate (ADC), GB01-VA-PL2202.

Researchers from Peptidream Inc. presented preclinical characterization of novel carbonic anhydrase IX (CAIX)-targeting radiopeptides, [64Cu]PD-32766 and [177Lu]PD-32766, being developed for the diagnosis and treatment of clear cell renal cell carcinoma (ccRCC), respectively.

Researchers from Egle Therapeutics SAS presented the discovery of a novel immunocytokine, EGL-001, designed to selectively target tumor-infiltrating regulatory T cells (Tregs).

Chong Kun Dang Pharm (CKD Pharm) has presented data on their c-Met-targeting antibody-drug conjugate (ADC) CKD-703 for the treatment of solid tumors. CKD-703 was designed based on site-specific conjugation, with a stable and homogeneous drug-antibody ratio profile.

Researchers from Axcynsis Therapeutics Pte. Ltd. presented the development and preclinical characterization of AT-2604, a novel antibody-drug conjugate (ADC) targeting the placental alkaline phosphatases, ALPP and ALPPL2.

Poly(ADP-ribose) polymerase 1 (PARP-1) plays a crucial role in DNA repair and represents the pivotal target for first-generation PARP inhibitors.